Galantamine Ameliorates Doxorubicin-Induced Cognitive Impairment in Female Rats via Modulation of Neuroinflammation, BDNF/TrkB Pathway and Synaptic Plasticity
Pharmaceuticals · 29.10.2026 · 19 (11) · 1709
DOI: 10.3390/ph19111709 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 29.10.2026. Verfasst von Sinan Saral und 5 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Recep Tayyip Erdoğan University Development Foundation.
Abstract (Originalsprache)
Background
Chemotherapy-related cognitive impairment is a debilitating neurocognitive syndrome with no approved treatment. Doxorubicin induces neuroinflammation, disrupts neurotrophic signaling, and impairs synaptic plasticity. Galantamine, an acetylcholinesterase inhibitor, has anti-inflammatory and neuroprotective properties. This study investigated the dose-dependent effects of galantamine (2.5 and 5 mg/kg) on cognitive behavior, neuroinflammation, the BDNF/TrkB pathway, and synaptic plasticity in a rat model of doxorubicin-induced cognitive impairment.
Methods
Female Sprague Dawley rats were divided into control, doxorubicin (4 mg/kg/week, i.p.), doxorubicin + galantamine (2.5 mg/kg/day, oral), and doxorubicin + galantamine (5 mg/kg/day, oral) groups. After four weeks, spatial learning and memory were assessed using the Morris water maze, and recognition memory using the novel object recognition test. Hippocampal IL-1β, IL-10, BDNF, and AChE levels were measured by ELISA. Histopathology was assessed by H&E staining. TrkB expression was evaluated by immunohistochemistry, and PSD-95 and synaptophysin by Western blot.
Results
Doxorubicin impaired spatial learning and memory and reduced discrimination index in the NOR test. Galantamine, especially at 5 mg/kg, attenuated these deficits. Doxorubicin increased IL-1β and AChE, while decreasing IL-10 and BDNF. Galantamine at both doses reversed IL-1β and AChE increases and increased BDNF; only the 2.5 mg/kg dose increased IL-10. Doxorubicin-induced neuronal shrinkage and apoptosis were ameliorated by galantamine. Doxorubicin upregulated TrkB, which was normalized by high-dose galantamine. Western blot showed that doxorubicin increased PSD-95 and decreased synaptophysin; galantamine did not alter PSD-95 but reversed the synaptophysin decrease at low dose.
Conclusions
Galantamine exerts dose-dependent neuroprotective effects against doxorubicin-induced cognitive impairment by reducing neuroinflammation, modulating BDNF and TrkB levels, and preserving presynaptic plasticity. These findings suggest galantamine as a potential option for preventing chemotherapy-related cognitive impairment.
Förderung
- Recep Tayyip Erdoğan University Development Foundation
Zitieren
APA
Saral, S., Sümer, A., Topçu, A., Mercantepe, T., Nalkıran, İ., & Saral, Ö. (2026). Galantamine Ameliorates Doxorubicin-Induced Cognitive Impairment in Female Rats via Modulation of Neuroinflammation, BDNF/TrkB Pathway and Synaptic Plasticity. Pharmaceuticals, 19(11), 1709. https://doi.org/10.3390/ph19111709
Vancouver
Saral S, Sümer A, Topçu A, Mercantepe T, Nalkıran İ, Saral Ö. Galantamine Ameliorates Doxorubicin-Induced Cognitive Impairment in Female Rats via Modulation of Neuroinflammation, BDNF/TrkB Pathway and Synaptic Plasticity. Pharmaceuticals. 2026;19(11):1709. doi:10.3390/ph19111709
BibTeX
@article{Saral2026,
author = {Saral, Sinan and Sümer, Ayşegül and Topçu, Atilla and Mercantepe, Tolga and Nalkıran, İhsan and Saral, Özlem},
title = {Galantamine Ameliorates Doxorubicin-Induced Cognitive Impairment in Female Rats via Modulation of Neuroinflammation, BDNF/TrkB Pathway and Synaptic Plasticity},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1709},
doi = {10.3390/ph19111709}
}
EUVIMED